• BioLineRx disclosed new preclinical findings on GLIX1, an oral cancer drug candidate, ahead of two abstracts scheduled for publication at the ASCO 2026 Annual Meeting on May 29–June 2.
• The data support GLIX1’s tumor-killing activity across multiple cancer models, with a development focus on glioblastoma.
• Separate preclinical work indicates GLIX1 could boost the effectiveness of PARP inhibitors, extending potential use into cancers that typically respond poorly to that drug class.
• A first-in-human Phase 1/2a trial in glioblastoma started in March and is enrolling patients, setting up the next value inflection point around initial clinical readouts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605220700PR_NEWS_USPR_____IO64128) on May 22, 2026, and is solely responsible for the information contained therein.